Intellia’s Landmark Phase 3 Results Show 87% Drop in HAE Attacks With Single Dose
Intellia Therapeutics (NASDAQ:NTLA) has announced a global first: its Phase 3 HAELO trial for hereditary angioedema (HAE) has not only met primary and key secondary endpoints but has done so with a one-time, in vivo CRISPR gene editing treatment. This milestone isn’t just a pivotal moment for Intellia—it could usher in an entirely new paradigm for treating rare genetic conditions like HAE, which until now have relied on burdensome, ongoing therapies.
Key Findings Highlight Prolonged, Drug-Free Relief for Most Patients
The HAELO Phase 3 trial tested lonvoguran ziclumeran (lonvo-z) in 80 adults and adolescents. Fifty-two received lonvo-z, while 28 received placebo. The results were striking: a single 50mg infusion of lonvo-z reduced HAE attack rates by 87% compared to placebo (mean monthly attacks of 0.26 vs. 2.10, p<0.0001) during the crucial six-month evaluation window. Equally compelling, 62% of patients in the lonvo-z group were both attack-free and therapy-free during this period, compared to just 11% in the placebo group.
| Endpoint | Lonvo-z Group | Placebo Group | Statistical Significance |
|---|---|---|---|
| Mean Monthly HAE Attacks | 0.26 | 2.10 | p < 0.0001 |
| Attack-Free & Therapy-Free (%) | 62% | 11% | p < 0.0001 |
| Total Patients Enrolled | 80 (52 lonvo-z, 28 placebo) | N/A | |
Favorable Safety Profile Supports Broad Appeal
The safety and tolerability picture for lonvo-z is encouraging. The most common side effects were mild or moderate, consisting primarily of infusion reactions, headaches, and fatigue. No serious adverse effects were observed in the treated population. Importantly, all patients treated with lonvo-z at the start or in crossover after week 28 remained free of long-term therapy (LTP) through the data cutoff date.
Regulatory Momentum: Rolling BLA Submission and Anticipated U.S. Launch
Intellia has already begun rolling its Biologics License Application (BLA) submission to the FDA, preparing for a potential U.S. launch in the first half of 2027. Backed by five key regulatory designations—including Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) in the U.S., and Priority Medicines (PRIME) in Europe—lonvo-z is positioned as a trailblazing therapy for a population historically underserved by existing treatments.
Potential Paradigm Shift in Hereditary Angioedema Treatment
HAE, a rare but life-threatening genetic disorder, has traditionally required frequent infusions or daily medication to manage symptoms. Existing therapies often fail to prevent breakthrough attacks entirely. Lonvo-z’s one-time dose model not only frees patients from chronic medication but also could reshape the patient and caregiver experience, minimizing anxiety and healthcare burden.
Takeaway: Investors and Patients Eye Lonvo-z’s Regulatory Path
With potential FDA approval on the horizon and additional data set for presentation at the European Academy of Allergy and Clinical Immunology Congress, lonvo-z sits at the forefront of CRISPR-based clinical innovation. If approved, the therapy could address critical unmet needs for HAE patients by offering lasting prevention with a single treatment. For stakeholders—from physicians to investors—this is a development to follow closely as the regulatory process unfolds.
Upcoming Events: Full data to be presented at EAACI Congress, June 12-15, Istanbul; Webcast of results at 8:00 a.m. ET today via Intellia’s website.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI